

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

Medication	Comments
Strattera (atomoxetine)	N/A

**VERRIDE(S)**

Prior Authorization of Benefits

**APPROVAL DURATION**

1 year

**APPROVAL CRITERIA**

Requests for Strattera (atomoxetine) may be approved if the following criteria are met:

I. Individual has been on Strattera (atomoxetine) in the past 180 days (medication samples/ coupons/ discount cards are excluded from consideration as a trial);

**OR**

II. Individual is 6 years of age or older; **AND**

III. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD); **AND**

IV. Individual has had a trial of **one** generic stimulant medication unless any of the following apply:

- A. Individual or individual’s family has a history of substance diversion or abuse; **OR**
- B. Individual has a diagnosis of anxiety or a tic disorder (such as, Tourette’s Syndrome); **OR**
- C. Parent/guardian does not wish to initiate therapy with a stimulant medication.

**Note:** Attention deficit hyperactivity disorder (ADHD) may also be referred to as attention deficit disorder (ADD). Strattera (atomoxetine) has a black box warning for suicidal ideation in children and adolescents. Strattera was noted to increase the risk of suicidal ideation in short-term studies in children or adolescents with ADHD. The risk of use with the clinical need should be considered. Comorbidities occurring with ADHD may be associated with an increase in the risk of suicidal ideation and/or behavior. Individuals who are started on therapy should be monitored closely for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in behavior. Strattera is approved for ADHD in pediatric and adult individuals and not approved for major depressive disorder.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.